Janssen’s Invokana (canagliflozin) Receives the US FDA’s Approval for Patients with Type 2 Diabetes and Diabetic Kidney Disease 

 Janssen’s Invokana (canagliflozin) Receives the US FDA’s Approval for Patients with Type 2 Diabetes and Diabetic Kidney Disease 

Janssen’s Invokana (canagliflozin) Receives the US FDA’s Approval for Patients with Type 2 Diabetes and Diabetic Kidney Disease

Shots:

  • The approval is based on P-III CREDENCE study evaluating the renal outcomes of Invokana + SoC vs PBO in 4,401 patients with T2D with stage II/III DKD and macroalbuminuria who were receiving SoC including ACE inhibitors & ARB
  • The P-III CREDENCE study resulted in 30% reduction in 1EPs i.e, end-stage kidney disease (ESKD), doubling of serum creatinine and renal or CV death along with the 39% reduction in the risk of hospitalization for HF
  • Invokana is an SGLT2 inhibitor indicated to lower blood glucose level in T2D adjunct to diet & exercise, to reduce CV events & risk of ESKD & is only therapy for T2D to treat DKD & risk of hospitalization for HF in patients with T2D & DKD

Click here to­ read full press release/ article | Ref: Janssen | Image: Pharma World

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post